This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
In the September issue of Pharmaceutical Executive, Lev Gerlovin addresses four main questions that US drugmakers must answer to cope with the evolving payer landscape given rising drug prices. To read the article, click the link below.
A new report from the Partnership for Health System Sustainability and Resilience EU Expert Advisory Group, supported by CRA, calls for a more strategic and...
In the first of a new series of CRA Insights on this topic, Aaron Everitt looks at how Keytruda and other branded and biosimilar manufacturers are preparing...
CRA is a proud sponsor of the conference that aims to increase the prominence of women through professional development, substantive legal discussion, and...
CRA is a proud sponsor of the conference focusing on the intersection of intellectual property and the biopharmaceutical industry, and will explore the law,...
